It is estimated that the prevalence of Addison’s disease in T1D is 0.3%.2 Therefore, glucocorticoid replacement must be carefully tailored and monitored closely to minimize hypoglycemic episodes and use insulin therapy safely. This evidence concerns the gene INS and type 1 diabetes mellitus.